Novel Vaccine Targeting Colonic Adenoma: a Pre-clinical Model

Abstract

Background: Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in the USA. Over 80% of CRC develop from adenomatous polyps. Hence, early treatment and prevention of adenomas would lead to a significant decrease of disease burden for CRC. MYB is a transcription factor that is overexpressed in both precancerous adenomatous polyps and colorectal cancer, and hence an ideal immunotherapeutic target. We have developed a cancer vaccine, TetMYB, that targets MYB and aim to evaluate its efficacy in the prophylactic and therapeutic management of adenomatous polyps. Material and Methods: Six- to eight-week-old Apc min/+ (Familial Adenomatous Polyposis model) and Apc580S (sp..